Author: Ana López-Vázquez (Spain)
Co-authors: Jose Vicente Dabad, Adriana De la Hoz Polo, Lucas Sanjuan, Mireia Roca Cabau, Isabel Mogollón Giralt, Miguel Del Piñal
Purpose
To present the case of a 44 year old male that referred blurred vision after the initiation of corticosteroid therapy for the treatment of systemic lupus erythematosus (SLE). We aim to describe the approach to the differential diagnosis between central serous chorioretinopathy (CSC) secondary to corticosteroid therapy or lupus choroidopathy.
Setting/Venue
Ophthalmology clinic - La Paz University Hospital. Madrid.
Methods
This study is conceived as a case presentation, consisting of the clinical and multimodal imaging data gathered by the same ophthalmologists in each visit, during and after the hospitalization of the patient due to severe SLE.
Results
A 44 year old patient arrived to the Emergency room presenting with anasarca and hypoproteinemia. Due to the finding of positive ANA titles as well as a renal biopsy showing class V nephritis the diagnose of SLE was made and high doses corticosteroid treatment was started. After several days, the patient referred loss of visual acuity (VA). On the first ophthalmological evaluation, visual acuity was 0.25 for the right eye (OD) and 0.4 for the left eye (OS). Funduscopic exam showed a massive neurosensory retinal detachment. Optical coherence tomography imaging (OCT) showed subretinal fluid up to temporal retinal vasculature and papilla on both eyes as well as multiple retinal pigment epithelium (RPE) detachments. Treatment with acetazolamide was initiated. However, the subretinal fluid kept increasing, and worsening of VA was proven (Worse VA achieved: OD: 0.125 OI: Counting fingers at 3 m), while systemic symptoms kept on improving with steroid treatment. Multimodal imaging such as indocyanine green and fluorescein angiography would have been useful, although they could not be performed due to compromised renal function. Improvement of systemic symptoms drove to tapering of the steroids resulting in subretinal fluid regression, achieving a final VA of 1 on both eyes.
Conlusions
Systemic lupus erythematosus is a heterogeneous rheumatic systemic disease with exceedingly varied clinical manifestations and a diverse pathogenesis. The presence of subretinal fluid during treatment of an outbreak makes it necessary to make the differential diagnosis between CSC and lupus choroidopathy. In our patient, the worsening of ocular findings with steroid treatment while systemics symptoms improved favored the diagnosis of CSC. It was also the more plausible diagnosis due to the reabsorption of the subretinal fluid and improvement of the visual symptoms secondary to tapering of steroids. Lupus choroidopathy is a rare clinical entity that has proven to be a risk factor for severe renal and central nervous system involvement, as well as an indicator of active disease. On reviewing the literature, lupus choroidopathy has shown to respond only to high corticosteroid doses in pulses, which not only improves the visual symptomps but also al the systemic manifestations. It is crucial to detect lupus choroidopathy on time not only to improve the visual acuity prognosis, but also the systemic one.
Financial Disclosure
No financial interests.
Comments
-